Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and rheumatism. 2013;65(1):1–11.

Ross C, Makhzoum J-P, Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2022;7(3):153–66.

Article  Google Scholar 

Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009;48(12):1560–5.

Article  PubMed  Google Scholar 

Kim MY, Sohn KH, Song WJ, Park HW, Cho SH, Min KU, et al. Clinical features and prognostic factors of Churg-Strauss syndrome. Korean J Intern Med. 2014;29(1):85–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saku A, Furuta S, Hiraguri M, Ikeda K, Kobayashi Y, Kagami SI, et al. Longterm outcomes of 188 Japanese patients with Eosinophilic granulomatosis with Polyangiitis. J Rhuematol. 2018;45(8):1159–66.

Article  Google Scholar 

Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthritis Rheum. 2013;65(1):270–81.

Article  PubMed  Google Scholar 

Zwerina J, Eger G, Englbrecht M, Manger B, Schett G. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum. 2009;39(2):108–15.

Article  PubMed  Google Scholar 

Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G et al. Churg-Strauss syndrome. Autoimmun Rev. 2015;14(4):341–8.

Pagnoux C, Berti A. Advances in the pharmacotherapeutic management of eosinophilic granulo matosis with polyangiitis. Expert Opin Pharmacother. 2023;24(11):1269–81.

Article  CAS  PubMed  Google Scholar 

Koike H, Nishi R, Furukawa S, Mouri N, Fukami Y, Iijima M, et al. In vivo visualization of eosinophil secretion in eosinophilic granulomatosis with polyangiitis: an ultrastructural study. Allergology International: Official J Japanese Soc Allergology. 2022;71(3):373–82.

Article  CAS  Google Scholar 

Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48–49:99–103.

Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S et al. Evidence-based guideline for the diagnosis and management of eosinophi lic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19(6):378–93.

Jerrentrup A, Müller T, Mariss J, Dylla S. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Internist (Berl). 2018;59(5):497–504.

Villa-Forte A. Eosinophilic granulomatosis with polyangiitis. Postgrad Med. 2023;135(sup1):52–60.

Trivioli G, Terrier B, Vaglio A. Eosinophilic granulomatosis with polyangiitis: understanding the disea se and its management. Rheumatology (Oxford, England). 2020;59(Suppl 3):iii84–iii94.

Cohen P, Pagnoux C, Mahr A, Arène J-P, Mouthon L, Le Guern V et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective mult icenter trial comparing glucocorticoids and six or twelve cyclophospha mide pulses in forty-eight patients. Arthritis and rheumatism. 2007;57(4):686–93.

Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Lauque D, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586–94.

Article  CAS  PubMed  Google Scholar 

Wang J, Zeng X-X, Cai W, Han Z-B, Zhu L-Y, Liu J-Y et al. Safety and efficacy of placenta-derived mesenchymal stem cell treatment for diabetic patients with critical limb ischemia: a pilot study. Exp Clin Endocrinol Diabetes. 2021;129(7):542–48.

Zeng X, Tang Y, Hu K, Jiao W, Ying L, Zhu L et al. Three-week topical treatment with placenta-derived mesenchymal stem Ce lls hydrogel in a patient with diabetic foot ulcer: a case report. Med (Baltim). 2017;96(51):e9212.

Martin-Rufino JD, Lozano FS, Redondo AM, Villaron EM, Rueda R, Fernandez-Samos R, et al. Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease). Stem Cell Res Ther. 2018;9(1):150.

Article  PubMed  PubMed Central  Google Scholar 

Arango-Rodríguez ML, Mateus LC, Sossa CL, Becerra-Bayona SM, Solarte-David VA, Ochoa Vera ME, et al. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells. Stem Cell Res Ther. 2023;14(1):221.

Article  PubMed  PubMed Central  Google Scholar 

Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findin gs, and therapeutic implications for cardiac disease. Circulation research. 2011;109(8):923–40.

Li X, Zhang D, Yu Y, Wang L, Zhao M. Umbilical cord-derived mesenchymal stem cell secretome promotes skin r egeneration and rejuvenation: from mechanism to therapeutics. Cell Prolif. 2024;57(4):e13586.

Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and po tential clinical utility. World journal of stem cells. 2014;6(2):195–202.

Guadix JA, Zugaza JL, Gálvez-Martín P. Characteristics, applications and prospects of mesenchymal stem cells in cell therapy. Med Clin (Barc). 2017;148(9):408–14.

Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8(8):886.

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al. The American College of Rheumatology 1990 criteria for the classificat ion of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100.

Pagnoux C, Nair P, Xi Y, Khalidi NA, Carette S, Cuthbertson D, et al. Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clinical and experimental rheumatology. Mar-Apr. 2019;37(117):40–4.

Google Scholar 

Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front Med. 2021;8:627776.

Article  Google Scholar 

Ramentol-Sintas M, Martínez-Valle F, Solans-Laqué R. Churg-Strauss syndrome: an evolving paradigm. Autoimmun Rev. 2012;12(2):235–40.

Article  PubMed  Google Scholar 

Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clinical and experimental rheumatology. 2011;29(1 Suppl 64):S23–34.

Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–53.

Article  PubMed  Google Scholar 

Navarro-Mendoza EP, Tobón GJ. Eosinophilic granulomatosis with polyangiitis: newer therapies. Curr Rheumatol Rep. 2018;20(5):23.

Article  Google Scholar 

Puéchal X, Pagnoux C, Baron G, Quémeneur T, Néel A, Agard C et al. Adding Azathioprine to remission-induction glucocorticoids for eosinop hilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 2017;69(11):2175–86.

Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 2010;19(6):667–79.

Article  PubMed  Google Scholar 

Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells Int. 2016;2016:6901286.

Article  PubMed  PubMed Central  Google Scholar 

Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105(10):4120–6.

Article  CAS  PubMed  Google Scholar 

Sharan J, Barmada A, Band N, Liebman E, Prodromos C. First report in a human of successful treatment of asthma with mesenchymal stem cells: a case report with review of literature. Curr Stem Cell Res Therapy. 2023;18(7):1026–29.

Article  CAS  Google Scholar 

Yi JZ, Chen ZH, Xu FH, Wang ZY, Zhang HQ, Jiang GS, et al. Interferon-γ suppresses the proliferation and migration of human placenta-derived mesenchmal stromal cells and enhances their ability to induce the generation of CD4(+)CXCR5(+)Foxp3(+)Treg subset. Cell Immunol. 2018;326:42–51.

Article  CAS  PubMed  Google Scholar 

Zhang A, Xiong Y, Xu F, Wang Z, Ma J, Zhao N, et al. IL-1β enhances human placenta-derived mesenchymal stromal cells ability to mediate Th1/Th2 and Th1/CD4(+)IL-10(+) T cell balance and regulates its adhesion, proliferation and migration via PD-L1. Cell Immunol. 2020;352:104113.

Article  CAS  PubMed  Google Scholar 

Mathias LJ, Khong SM, Spyroglou L, Payne NL, Siatskas C, Thorburn AN et al. Alveolar macrophages are critical for the inhibition of allergic asthma by mesenchymal stromal cells. Journal of immunology (Baltimore, Md: 1950). 2013;191(12):5914-24.

Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner D, McKenna DH, et al. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. Stem Cells Translational Med. 2015;4(6):615–24.

Article  CAS  Google Scholar 

Zeng X, Tang Y, Hu K, Jiao W, Ying L, Zhu L, et al. Three-week topical treatment with placenta-derived mesenchymal stem cells hydrogel in a patient with diabetic foot ulcer: a case report. Med (Baltim). 2017;96(51):e9212.

Article  Google Scholar 

Gupta PK, Krishna M, Chullikana A, Desai S, Murugesan R, Dutta S, et al. Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger’s disease: phase II study report suggests clinical efficacy. Stem Cells Translational Med. 2017;6(3):689–99.

Article  Google Scholar 

Zhang C, Huang L, Wang X, Zhou X, Zhang X, Li L, et al. Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up. Stem Cell Res Ther. 2022;13(1):451.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Świerczek-Lasek B, Tolak L, Bijoch L, Stefaniuk M, Szpak P, Kalaszczynska I et al. Comparison of muscle regeneration after BMSC-conditioned medium, syngeneic, or allogeneic BMSC injection. Cells. 2022/9/12/;11(18):2843.

Piao L, Huang Z, Inoue A, Kuzuya M, Cheng XW. Human umbilical cord-derived mesenchymal stromal cells ameliorate aging-associated skeletal muscle atrophy and dysfunction by modulating apoptosis and mitochondrial damage in SAMP10 mice. Stem Cell Res Ther. 2022;13(1):226.

Article  CAS  PubMed  PubMed Central  Google Scholar